Get the Stockscreener App
1.65
5.17%
-0.09
Alx Oncology Holdings Inc stock is traded at $1.65, with a volume of 560.29K.
It is down -5.17% in the last 24 hours and up +1.85% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.74
Open:
$1.8
24h Volume:
560.29K
Relative Volume:
0.58
Market Cap:
$87.03M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.5556
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
+3.77%
1M Performance:
+1.85%
6M Performance:
-73.17%
1Y Performance:
-87.60%
1-Day Range:
$1.6301
$1.80
1-Week Range:
$1.56
$1.80
52-Week Range:
$1.19
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.65 | 87.03M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology to Host Virtual Company Event Highlighting - GlobeNewswire
ALX Oncology to Present Crucial Evorpacept Cancer Trial Data at ASCO GI Symposium - StockTitan
ALX Oncology launches new equity incentive plan - MSN
ALX Oncology launches new equity incentive plan By Investing.com - Investing.com South Africa
ALX Oncology Adopts 2025 Inducement Equity Plan - TipRanks
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in December - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jane Street Group LLC Trims Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Barclays PLC Buys 42,185 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
State Street Corp Trims Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Alx oncology interim CFO Pinto sells $2,253 in stock By Investing.com - Investing.com Australia
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares - MarketBeat
Alx Oncology president sells $17,059 in stock By Investing.com - Investing.com Nigeria
Alx Oncology president sells $17,059 in stock - Investing.com
Alx oncology interim CFO Pinto sells $2,253 in stock - Investing.com
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Up 17.0% in December - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short Interest - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Jefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to Hold - Defense World
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
ALX Oncology’s (ALXO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Alx Oncology Holdings Inc (ALXO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
ALX Oncology falls as Jefferies cuts on lead cancer drug - MSN
ALX Oncology stock falls on Jefferies downgrade (ALXO:NASDAQ) - Seeking Alpha
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Investing.com Canada
ALX Oncology (NASDAQ:ALXO) Rating Lowered to Hold at Jefferies Financial Group - MarketBeat
ALX Oncology shares target steady, hold rating on positive clinical results - Investing.com Canada
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
ALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
HC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat
ALX Oncology to Present Updated Results from Phase 2 - GlobeNewswire
ALX Oncology to Present Key Phase 2 Gastric Cancer Trial Data at ASCO GI 2025 Symposium - StockTitan
Verition Fund Management LLC Acquires 100,454 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer - Nasdaq
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 - The Manila Times
ALX Oncology Sets Key Data Review: Evorpacept Breast Cancer Trial Results From SABCS 2024 - StockTitan
Fmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):